#rt pcr test report

[saudcncpathlab]

https://www.cncpathlab.com/blogs/new-strain-of-covid-and-it-rsquo-s-symptom

New Strain of COVID and a Symptoms

Rising Covid cases in China are substantially driven by the BF.7 strain of Omicron variant of coronavirus, which has been detected in India too. Figures may be small but then why the government is upset, and what you should be alert to. The high transmissibility means that the new sub variant could become the most dominant variant in the future, causing another covid wave. The WHO clarified that till the new variant is studied further and significant differences are identified, it will continue to be categorised as part of the Omicron variant. Three cases of BF.7 strain, that is driving the current wave of Covid infections in China, have been detected in India so far. Meanwhile, the virus has caused great distress around the globe including in the US, Hong Kong, South Kore, Japan, and Brazil. The R0 value of this mutant as per studies is approximately 10-18.6 which means that any infected individual can infect 10-18.6 people around him. Also, there is quicker infection rate of this virus, in hours. The best way to detect it is COVID-19 RTPCR Test. 

[covid-safer-hotties]

Long COVID is not the same for everyone: a hierarchical cluster analysis of Long COVID symptoms 9 and 12 months after SARS-CoV-2 test - Published Sept 19, 2024

Abstract Background Identifying symptom clusters in Long COVID is necessary for developing effective therapies for this diverse condition and improving the quality of life of those affected by this heterogeneous condition. In this study, we aimed to identify and compare symptom clusters at 9 and 12 months after a SARS-CoV-2 positive test and describe each cluster regarding factors at infection.

Methods This is a cross-sectional study with individuals randomly selected from the Portuguese National System of Epidemiological Surveillance (SINAVE) database. Individuals who had a positive RT-PCR SARS-CoV-2 test in August 2022 were contacted to participate in a telephonic interview approximately 9 and 12 months after the test. A hierarchical clustering analysis was performed, using Euclidean distance and Ward’s linkage. Clustering was performed in the 35 symptoms reported 9 and 12 months after the SARS-CoV-2 positive test and characterised considering age, sex, pre-existing health conditions and symptoms at time of SARS-CoV-2 infection.

Results 552 individuals were included at 9 months and 458 at 12 months. The median age was 52 years (IQR: 40–64 years) and 59% were female. Hypertension and high cholesterol were the most frequently reported pre-existing health conditions. Memory loss, fatigue or weakness and joint pain were the most frequent symptoms reported 9 and 12 months after the positive test. Four clusters were identified at both times: no or minor symptoms; multi-symptoms; joint pain; and neurocognitive-related symptoms. Clusters remained similar in both times, but, within the neurocognitive cluster, memory loss and concentration issues increased in frequency at 12 months. Multi-symptoms cluster had older people, more females and more pre-existing health conditions at 9 months. However, at 12 months, older people and those with more pre-existing health conditions were in joint pain cluster.

Conclusions Our results suggest that Long COVID is not the same for everyone. In our study, clusters remained similar at 9 and 12 months, except for a slight variation in the frequency of symptoms that composed each cluster. Understanding Long COVID clusters might help identify treatments for this condition. However, further validation of the observed clusters and analysis of its risk factors is needed.

[darkmaga-returns]

A Scientific Explanation of the Fraud of RT-PCR Testing for COVID-19

Corinne Michels

Nov 05, 2024

“The COVID-19 PCR tests were a fraud.” You have heard this before, but is it true or just more hype? Read this report and decide for yourself. It explains the fundamentals of the RT-PCR (Reverse Transcriptase - Polymerase Chain Reaction) test kits for those who want to understand the facts. Do not expect an easy read. For starters, you will need to familiarize yourself with the basic structure of DNA. Understanding how misinterpretation of the RT-PCR test results was used to create the COVID-19 pandemic will be your reward. You will be immunized against future efforts to create fear and societal discord. Rest assured; they will try again!

A serious flu-like respiratory disease began to spread in early Fall 2019 with Wuhan, China, as “ground zero.” By December, worldwide spread of the disease was underway. Images of hapless pedestrians suddenly falling dead in the streets; overwhelmed hospitals in Lombardy, Italy; government-imposed lockdowns; and nonstop coverage of worldwide COVID deaths fanned the flames of fear surrounding this unknown disease. It was not enough to be symptom-free. People demanded the development of a test to detect silent carriers of the infectious agent.

Only the genome sequence of SARS-CoV-2 was known at the time, and the only available testing method used polymerase chain reaction, a.k.a. PCR. Despite many known contraindications, RT-PCR widespread testing for COVID-19 began. According to Dr. Trish M. Perl, an epidemiologist at Johns Hopkins and past president of the Society of Health Care Epidemiologists of America, blind faith in the results of technically complex molecular tests results in “pseudo-epidemics.”  [https://www.nytimes.com/2007/01/22/health/22whoop.html] The COVID-19 pandemic was one of those.

[mariebenz]

Trained Scent Dogs Can Quickly and Accurately Detect Covid-19

MedicalResearch.com Interview with: Prof. Tommy Dickey Ph.D. Distinguished Professor Emeritus Geography Department University of California Santa Barbara Santa Barbara, CA

MedicalResearch.com: What is the background for this study? Response:  I became interested in dog's sense of smell several years ago while doing therapy dog demonstrations at the California Science Center in Los Angeles during a special traveling exhibit "Dogs! A Science Tail." (Now at the Orlando Science Center).  I did a lot of research on this topic and taught children about it through the Los Angeles Public Library using my Great Pyrenees therapy dogs. Then, COVID broke out and I expanded my research into any work being done to possibly utilize scent dogs for screening and testing for COVID.  I found only a few such studies.  However, I fortuitously met Heather Junqueira of BioScent, Inc. (in Florida) online and she was beginning to successfully teach her beagles to detect COVID-related odors.  She agreed to co-author a peer-reviewed review paper with me.  That led to our first paper - Dickey, T, Junqueira, H. Toward the use of medical scent dogs for COVID-19 screening. J Osteopath Med 2021;1(2): 141-148. https://doi.org/10.1515/jom-2020-0222 When the COVID pandemic began to wane at the beginning of this year, I felt that it would be the perfect time to do this comprehensive follow-up review to see how far COVID scent dog research had progressed. To our amazement, research efforts had increased by almost tenfold and involved over 400 scientists using over 31,000 samples (including sniffings) from over 30 countries and that 29 peer reviewed papers had been published. Heather’s inspiration for doing scent dog work came when her father contracted cancer and she wanted to find better diagnostics.  She has since been successful in detecting non-small cell lung cancer with her trained beagles as well as COVID. MedicalResearch.com: Would you tell us a little about the type and/or breeding of the dogs? Response:  In the peer-reviewed studies, the number of different breeds and mixed breeds was 19.   Typical training periods dedicated to COVID scent detection were a few weeks. Labrador Retrievers and Belgian Malinois were most commonly used (nearly 100 times). These breeds were chosen because they have been used extensively in scent detection work for several purposes.  Other breeds, such as Heather’s beagles, have been used quite successfully as well. No obvious preference based on performance has been noted by breed, age, gender, age or even previous training for scent work. Interestingly, most of the dogs were not specifically bred to do COVID detection.  In fact, previously untrained dogs have the advantage that they are not as prone to indicating on scents other than the COVID-19 associated scent. Heather is one of the few scientists who actually breeds her dogs to be single purpose scent dogs (i.e., for COVID or other diseases). MedicalResearch.com: What are the main findings? 1)    Our review has shown that it safe to utilize scent dogs to directly screen and test individuals who may be infected with the COVID-19. 2)    The accuracy of the trained scent dog method is comparable to or in some cases superior to the real-time reverse transcription polymerase chain reaction (RT-PCR) test and the antigen (RAG) test. 3)    Trained scent dogs can be effectively used to provide quick (seconds to minutes), non-intrusive, and accurate results in public settings and thus reduce the spread of COVID. MedicalResearch.com: What should readers take away from your report? - Medical scent dogs deserve their place as a serious diagnostic methodology that could be particularly useful during pandemics, potentially as part of rapid health screenings in public spaces. We are confident that scent dogs will be useful in detecting a wide variety of diseases in the future. - We feel that the impressive international COVID scent dog research described in our paper, perhaps for the first time, demonstrates that medical scent dogs are ready for mainstream medical applications.  MedicalResearch.com: What recommendations do you have for future research as a results of this study? 1)    More studies utilizing more dogs would be beneficial 2)    More work in developing target samples is needed 3)    More research is needed in different public settings. MedicalResearch.com: Is there anything else you would like to add? Any disclosures? - More trained dogs will be needed for wide-spread, large-scale scent dog screening and testing.   The training and field use of scent dogs may benefit from the recruitment of dog owners who are already involved in recreational scent work under the auspices of the American Kennel Club and other organizations worldwide. - Is the use of scent dogs cost effective?  Much of the research in this review was in fact motivated by the need for rapid, inexpensive, and lower technological testing in developing nations.  More research into the economics is needed. - Perhaps the greatest challenge to the use of medical scent dogs is the implementation of wide-spread, large-scale programs, which will require funding and development of infrastructure that is responsible for certification, protocol standards, and deployments. This may be more of a challenge in the U.S. for a variety of bureaucratic reasons. Other nations face a variety of obstacles, but the large number of scent dogs already used in practical applications (seen in our paper’s References and Tables) suggests that their governments are quite supportive of the common use of medical scent dogs and may not place as many governmental barriers. Citation: Dickey, Tommy and Junqueira, Heather. "COVID-19 scent dog research highlights and synthesis during the pandemic of December 2019−April 2023" Journal of Osteopathic Medicine, 2023. https://doi.org/10.1515/jom-2023-0104 The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.     Read the full article

[krill-joy]

Medical Masks Versus N95 Respirators for Preventing COVID-19 Among Health Care Workers

Abstract

Background: It is uncertain if medical masks offer similar protection against COVID-19 compared with N95 respirators.

Objective: To determine whether medical masks are noninferior to N95 respirators to prevent COVID-19 in health care workers providing routine care.

Design: Multicenter, randomized, noninferiority trial. (ClinicalTrials.gov: NCT04296643).

Setting: 29 health care facilities in Canada, Israel, Pakistan, and Egypt from 4 May 2020 to 29 March 2022.

Participants: 1009 health care workers who provided direct care to patients with suspected or confirmed COVID-19.

Intervention: Use of medical masks versus fit-tested N95 respirators for 10 weeks, plus universal masking, which was the policy implemented at each site.

Measurements: The primary outcome was confirmed COVID-19 on reverse transcriptase polymerase chain reaction (RT-PCR) test.

Results: In the intention-to-treat analysis, RT-PCR–confirmed COVID-19 occurred in 52 of 497 (10.46%) participants in the medical mask group versus 47 of 507 (9.27%) in the N95 respirator group (hazard ratio [HR], 1.14 [95% CI, 0.77 to 1.69]). An unplanned subgroup analysis by country found that in the medical mask group versus the N95 respirator group RT-PCR–confirmed COVID-19 occurred in 8 of 131 (6.11%) versus 3 of 135 (2.22%) in Canada (HR, 2.83 [CI, 0.75 to 10.72]), 6 of 17 (35.29%) versus 4 of 17 (23.53%) in Israel (HR, 1.54 [CI, 0.43 to 5.49]), 3 of 92 (3.26%) versus 2 of 94 (2.13%) in Pakistan (HR, 1.50 [CI, 0.25 to 8.98]), and 35 of 257 (13.62%) versus 38 of 261 (14.56%) in Egypt (HR, 0.95 [CI, 0.60 to 1.50]). There were 47 (10.8%) adverse events related to the intervention reported in the medical mask group and 59 (13.6%) in the N95 respirator group.

Limitation: Potential acquisition of SARS-CoV-2 through household and community exposure, heterogeneity between countries, uncertainty in the estimates of effect, differences in self-reported adherence, differences in baseline antibodies, and between-country differences in circulating variants and vaccination.

Conclusion: Among health care workers who provided routine care to patients with COVID-19, the overall estimates rule out a doubling in hazard of RT-PCR–confirmed COVID-19 for medical masks when compared with HRs of RT-PCR–confirmed COVID-19 for N95 respirators. The subgroup results varied by country, and the overall estimates may not be applicable to individual countries because of treatment effect heterogeneity.

Primary Funding Source: Canadian Institutes of Health Research, World Health Organization, and Juravinski Research Institute.

[medtalksblog]

Chandipura Virus and Its Role in Viral Encephalitis

Chandipura virus (CHPV) is an emerging pathogen responsible for viral encephalitis outbreaks, particularly in India. First identified in 1965 in Chandipura village, Maharashtra, CHPV belongs to the Rhabdoviridae family. It has gained notoriety for causing acute encephalitis syndrome (AES), primarily in children, with high mortality rates. While not as globally known as other encephalitis-causing viruses, CHPV poses a significant public health challenge in affected regions.

Epidemiology and Outbreaks

CHPV outbreaks have been reported sporadically across India, with the states of Maharashtra, Gujarat, and Andhra Pradesh being most affected. The virus predominantly impacts children aged between 2 and 16 years. CHPV transmission occurs via sandflies (Phlebotomus spp. and Sergentomyia spp.), which thrive in warm and humid environments. Outbreaks often coincide with the monsoon season, as the vector population increases during this period. The mortality rate in CHPV-induced encephalitis is alarmingly high, with many cases proving fatal within 48 to 72 hours of symptom onset.

Transmission and Pathogenesis

CHPV is transmitted through the bite of an infected sandfly. Once the virus enters the human body, it spreads rapidly through the bloodstream to multiple organs, including the brain. The exact mechanism by which CHPV crosses the blood-brain barrier is not fully understood, but it is believed that the virus either infects immune cells or directly invades the cells lining the blood vessels. Once inside the central nervous system (CNS), CHPV causes severe inflammation, leading to encephalitis. Neuronal damage, cell death, and brain swelling are the hallmark features of this disease.

The incubation period for CHPV is typically 2 to 7 days, after which symptoms such as high fever, seizures, altered mental status, and coma rapidly develop. Due to the fast progression of the disease, it often proves fatal in a short time, especially in children with weakened immune systems.

Clinical Symptoms and Diagnosis

The symptoms of CHPV-induced encephalitis are often nonspecific and overlap with other viral encephalitis, making early diagnosis challenging. Common symptoms include:

High fever

Headache

Vomiting

Convulsions

Altered consciousness

Coma

Laboratory confirmation of CHPV involves detecting viral RNA in blood or cerebrospinal fluid (CSF) samples using reverse transcription-polymerase chain reaction (RT-PCR). Additionally, serological tests that detect CHPV-specific IgM antibodies can aid in diagnosis. Early detection is critical due to the disease's rapid progression.

Treatment and Management

No specific antiviral treatment exists. Supportive care involves managing fever, seizures, and brain swelling. Antipyretics, anticonvulsants, and diuretics like mannitol are used to reduce intracranial pressure. Severe cases may require intensive care and intravenous fluids.

Preventive strategies focus on vector control:

Using insect repellent

Installing bed nets

Wearing protective clothing

Reducing sandfly breeding sites

Public health efforts emphasize community awareness and early outbreak detection.

Research and Future Directions 

Ongoing research is exploring the virus's mechanisms and potential vaccines. Innovative technologies are also being studied to enhance CHPV management and prevention strategies.

Conclusion 

CHPV is a serious cause of viral encephalitis in India, with a high fatality rate among children. Early diagnosis and supportive care are essential, while research and preventive efforts remain critical to control future outbreaks.

[iamnaturalnana]

Measles Vaccine Virus RNA in Children More Than 100 Days after Vaccination

In routine diagnostic testing, we used two real-time reverse transcription-polymerase chain reaction (RT-rPCR) assays targeting M and F genes to identify measles virus (MeV) and MeVV RNA. Confirmatory testing was performed with an N gene RT-rPCR, followed by sequence confirmation of RT-rPCR positives by semi-nested conventional RT-PCR assays targeting portions of the N, H, and L genes. We report…

[neha24blog]

COVID-19 Detection Kits Market Expected To Witness A Substantial Growth Of USD 4.06 Billion By 2030: Grand View Research Inc.

San Francisco, 6 Sep 2024: The Report COVID-19 Detection Kits Market Size, Share & Trends Analysis Report By Product (RT-PCR Assay Kits), By Sample Type (Nasopharyngeal), By Mode (Centralized Testing), By End-use (Laboratories), By Region, And Segment Forecasts, 2024 – 2030 The global COVID-19 detection kits market size is expected to reach USD 4.06 billion by 2030, according to a new report by…

[businessmarketreports]

The Evolution of the COVID-19 Test Devices Market: From Early Pandemic to Present Day

The COVID-19 pandemic triggered a rapid and unprecedented surge in demand for diagnostic testing devices. As the pandemic unfolded, the market for COVID-19 tests underwent a remarkable transformation, characterized by rapid innovation, technological advancements, and increased global production capacity.

Buy the Full Report for More Insights on the COVID-19 Tests Market Forecast, Download a Free Sample Report

Early Pandemic: A Rush for Testing Devices

Initial Shortages: The early stages of the pandemic were marked by severe shortages of testing devices, particularly in regions with high infection rates. This scarcity hindered efforts to contain the virus and understand its spread.

Rapid Innovation: In response to the urgent need, manufacturers, researchers, and governments worldwide accelerated the development of new testing technologies, including RT-PCR, antigen tests, and rapid point-of-care (POC) tests.

Scaling Up Production: Global efforts were made to scale up the production of testing devices, leveraging existing manufacturing capabilities and establishing new facilities.

Advancements in Testing Technologies

RT-PCR Tests: Reverse-transcriptase polymerase chain reaction (RT-PCR) tests remained the gold standard for COVID-19 diagnosis, offering high sensitivity and specificity. However, their complexity and turnaround time limited their widespread use.

Antigen Tests: Rapid antigen tests, while less sensitive than RT-PCR, provided faster results and were more suitable for mass testing and screening purposes.

Point-of-Care Tests: POC tests, often lateral flow immunoassays, offered rapid results at the point of care but faced challenges in terms of sensitivity and specificity.

Saliva-Based Tests: The development of saliva-based testing simplified sample collection and made testing more accessible to the general public.

Market Expansion and Competition

Increased Production Capacity: Global manufacturers expanded their production capacities to meet the surging demand for COVID-19 tests.

New Market Entrants: Many new companies entered the market, driven by the lucrative opportunities presented by the pandemic.

Intense Competition: The market became highly competitive, with manufacturers vying for market share through price reductions, technological advancements, and improved turnaround times.

Challenges and Future Trends

Variant Challenges: The emergence of new COVID-19 variants, such as Omicron, posed challenges for testing devices, requiring adaptations to maintain accuracy.

Long-Term Demand: As the pandemic evolves, the long-term demand for COVID-19 tests remains uncertain, potentially impacting market dynamics.

Dual-Use Technologies: Some testing technologies, particularly those developed for COVID-19, have the potential to be repurposed for other infectious diseases, creating new market opportunities.

Home Testing: The increasing availability of at-home COVID-19 tests is changing the landscape of testing, empowering individuals to take control of their health.

The COVID-19 pandemic has significantly transformed the testing devices market, driving rapid innovation, increased production capacity, and a surge in demand. As the pandemic evolves, the market is likely to continue adapting to new challenges and opportunities, shaping the future of infectious disease testing.

[covid-safer-hotties]

Dutch participatory surveillance framework for evaluating evolutionary changes on SARS-CoV-2 affecting Rapid Diagnostic Test sensitivity in 2022 –2023 - Preprint Posted Sept 10, 2024

An interesting preprint that shows us water does indeed make things wet: The majority of rapid test negatives come from human error (first and foremost, not using RATs to serial test)

Abstract Background Rapid Diagnostic Tests (RDTs) have been pivotal in the diagnostics for SARS-CoV-2 and policies surrounding self-isolation. When self-testing policies are in place a decreased sensitivity of the virus to RDTs can give benefits for viral spread. However, to monitor for reduced sensitivity of RDTs we rely on the collection of SARS-CoV-2 positive samples from RDT negative patients. Infectieradar, a national participatory surveillance that registers influenza-like symptoms is used as a framework to study false-negative RDT results due to emergence of new virus variants.

Methods Participants report weekly on RDT use and symptoms linked to Acute Respiratory Illness (ARI). Each week, all RDT positive and a sample of 200 among RDT negative but symptomatic participants were invited to send in nose throat swabs (NTS). SARS-CoV-2 Ct-values are determined using RT-PCR on NTS samples for RDT positive and RDT (false) negative participants and compared. Sequencing is performed on all eligible samples for phylogenetic analysis of the SARS-CoV-2 nucleocapsid protein and the whole genome sequence. NTS samples of participants with discordant RT-PCR and RDT results are also analyzed using RDTs by professionals in the laboratory.

Results Between October 2022 and October 2023, our study had 16,893 participants and we collected 1,757 self-test-positive/NTS PCR positive samples and 359 self-test-negative/NTS PCR positive samples (RDT-/PCR+). These participants were asked to take a SARS-CoV-2 RDT upon symptoms. Within SARS-CoV-2 PCR positive participants, we did not find characteristics that differ in SARS-CoV-2 RDT negative versus positive participants. There were no associations with specific changes in the N protein nor did our phylogenetic analysis show clustering of RDT negative samples.

Conclusion Evaluating brand-specific RDT performance in Dutch population and false-negative RDT analyses, led to no evidence for SARS-CoV-2 evolution affecting RDT sensitivity. The participatory surveillance program Infectieradar is a powerful tool for our national surveillance on acute respiratory illnesses, as well as for research purposes. Since this framework offered both self-testing and the gold standard of PCR testing results.

[darkmaga-returns]

A Scientific Explanation of the Fraud of RT-PCR Testing for COVID-19

Corinne Michels

Nov 05, 2024

“The COVID-19 PCR tests were a fraud.” You have heard this before, but is it true or just more hype? Read this report and decide for yourself. It explains the fundamentals of the RT-PCR (Reverse Transcriptase - Polymerase Chain Reaction) test kits for those who want to understand the facts. Do not expect an easy read. For starters, you will need to familiarize yourself with the basic structure of DNA. Understanding how misinterpretation of the RT-PCR test results was used to create the COVID-19 pandemic will be your reward. You will be immunized against future efforts to create fear and societal discord. Rest assured; they will try again!

A serious flu-like respiratory disease began to spread in early Fall 2019 with Wuhan, China, as “ground zero.” By December, worldwide spread of the disease was underway. Images of hapless pedestrians suddenly falling dead in the streets; overwhelmed hospitals in Lombardy, Italy; government-imposed lockdowns; and nonstop coverage of worldwide COVID deaths fanned the flames of fear surrounding this unknown disease. It was not enough to be symptom-free. People demanded the development of a test to detect silent carriers of the infectious agent.

Only the genome sequence of SARS-CoV-2 was known at the time, and the only available testing method used polymerase chain reaction, a.k.a. PCR. Despite many known contraindications, RT-PCR widespread testing for COVID-19 began. According to Dr. Trish M. Perl, an epidemiologist at Johns Hopkins and past president of the Society of Health Care Epidemiologists of America, blind faith in the results of technically complex molecular tests results in “pseudo-epidemics.”  [https://www.nytimes.com/2007/01/22/health/22whoop.html] The COVID-19 pandemic was one of those.

[trendingreportz]

Cancer Testing Screening Market - Forecast(2024 - 2030)

Cancer Testing Screening Market Overview

Cancer Testing Screening Market size is projected to reach $220.66 billion by 2027 and is expected to grow at a CAGR of 6.4% during the forecast period 2022-2027. Cancer Testing and Screening are vital procedures for aid in the early detection of cancer before symptoms occur. It lowers the risk of malignant cells growing abnormally and lowers the person's mortality rates. Each type of cancer has a screening test that can help spot cancer early on. There is increasing adoption of cancer screening tests, particularly in countries with the highest cancer rates. The improved research and development activities coupled with the increasing public awareness of cancer diseases are all predicted to create a new window of opportunities in the global cancer Testing screening market. However, COVID-19 has restrained the market growth. The lack of adequate supplies needs for more service providers added to the crises, thereby restraining the market growth.

Cancer Testing Screening Market Report Coverage

The report: “Cancer Testing Screening Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Cancer Testing Screening Market.

By Type: Diagnostics, Screening. By Cancer Type: Respiratory System Cancer, Leukemia, Myeloma and Lymphoma, Skin Cancer, Abdominal/Digestive System Cancer, Genital Cancer, Oral Cancer, Urinary System Cancer, Endocrine System Cancer, Breast Cancer, Others. By Technique: Imaging, Biopsy, Genomic and Molecular Tests (Next Generation Sequencing, RT-PCR, Microarrays, Biomarker Testing, Others. By Product Type: Molecular Diagnostics, Companion Diagnostics. By Stage: Terminal, Stage 0-4, Prognosis, Other Staging System. By Gender: Male, Female. By Geography: Americas (U.S, Canada, Brazil, Rest of Americas), Europe (U.K, Germany, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, India, and South Korea), and Rest of the World (Middle East, Africa).

Request Sample

Key Takeaways

Geographically, The Americas Cancer Testing Screening market accounted for the highest revenue share in 2021, followed by Europe. This is owing to the steady rise of Lung and Prostate Cancer cases in both regions which are being driven by the adoption of unhealthy lifestyles such as excessive alcohol consumption and smoking.

The increasing number of cancer cases around the world is unfortunate. However, it is beneficial to the cancer screening industry. The industry is also being propelled forward by Increased research and development (R&D) to develop effective cancer treatments and early detection. Innovative technologies including positron emission mammography, spectroscopy-enhanced colonoscopy, and hyperpolarization MRI, among others, are improving screening efficiency.

Cancer Testing Screening Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Cancer Testing Screening Market report.

Cancer Testing Screening Market Segment Analysis – By Cancer Type

The Cancer Testing Screening Market based on Cancer Type can be segmented into Respiratory System Cancer, Leukemia, Myeloma, and Lymphoma, Skin Cancer, Abdominal/Digestive System Cancer, Genital Cancer, Oral Cancer, Urinary System Cancer, Endocrine System Cancer, Breast Cancer, and Others. Abdominal/Digestive system cancer had the largest share in the cancer testing screening market in 2021 and is expected to grow at a CAGR of 5.9% owing to the rise in consumption of processed food and alcohol. Additionally, the increase in the global geriatric population has generated demand for imaging devices for early detection and treatment of Abdominal cancer, thereby driving the segment. According to the Organization of the United Nations, the proportion of people aged 65 and up in the global population climbed from 6% in 1990 to 9% in 2019. By 2050, that percentage is expected to climb to 16%, implying that one in every six individuals on the planet is predicted to be 65 or older.

Inquiry Before Buying

Cancer Testing Screening Market Segment Analysis – By Technique

The Cancer Testing Screening Market based on the Technique can be segmented into Imaging, Biopsy, Genomic and Molecular Tests (Next Generation Sequencing, RT-PCR, Microarrays, Biomarker Testing, and Others. Biopsy technique dominated the Cancer testing screening Market in 2021 and is expected to grow at a CAGR of 6.2%. This is owing to its high accuracy during Cancer Diagnosis. Other Diagnostic advances, such as imaging techniques, have increased demand for cancer testing and screening. Imaging has become an important aspect of cancer detection and diagnosis, with recent advancements in tumor imaging technologies improving the diagnosis of five common cancers, including breast, lung, prostate, and colorectal cancers.

Cancer Testing Screening Market Segment Analysis – By Geography

The Cancer Testing Screening Market based on Geography can be segmented into Americas, Europe, Asia-Pacific, and the Rest of the World. Americas region dominated the cancer screening/testing market in 2021 with a market share of 41% and is growing at a CAGR of 4.5% during the forecast period 2022-2027. This is owing to the high rate of new cancer cases each year along with increased awareness amongst the masses.

 However, Asia Pacific is set to be the fastest-growing segment with a CAGR of 11% during the forecast period 2022-2027. This is owing to the growing rate of endocrine, abdominal, leukemia, myeloma, and lymphoma cancers in the Asia Pacific region. 

Schedule a Call

Cancer Testing Screening Market Drivers

Growing Number Of Cancer Screening Awareness Campaigns To Raise Awareness About The Importance Of Early Detection Of Breast Cancer Is To Drive Market Growth

Several governmental and commercial groups are launching various campaigns to raise awareness about the importance of early detection of breast cancer, the second most frequent cancer among women in the United States. Breast Cancer Diagnostics Market Growth Depends on Cancer Awareness Campaigns. Nations around the globe have initiated various Cancer Screening Awareness Campaigns to encourage young people to make these life-saving behaviors part of their daily routine. For example, Breast cancer campaigns, Cervical cancer awareness campaigns, Protect Your Skin campaigns, Ovarian cancer awareness campaigns and Colorectal cancer awareness campaigns are among the few impacting the growth of the cancer screening and diagnostics market. For instance, the 'Be Clear on Cancer campaign has substantially increased the number of referrals under the 2WW rule. This has increased demands on both resources (59% more tests) and finance. Cost per cancer detected rose by 27% with no increase in funding to support the increased activity.

Technological Advancements And Automation In Cancer Testing And Screening Is To Fuel Service Demand

Cancer testing has become more accurate and user-friendly as a result of technological developments and automation, which has aided industry growth. Novel screening technologies have largely been adopted owing to their ability to increase tumor detection rates. Additionally, the cancer testing & screening market is likely to be driven by the approval of novel biomarkers and increased R&D spending. The key players in the market are increasingly investing in AI-based imaging biomarkers. For instance, Brainomix has invested $21.2 million for the development of an AI platform that automates validated imaging biomarkers to improve both diagnosis and treatment decisions to build on the proven success of the company's tech platform in stroke and enable value-generating pharmaceutical partnerships. Proteomics and genomics are two OMICS technologies that will propel the cancer testing & screening industry forward.

Cancer Testing Screening Market Challenges

High Cost Of Cancer Diagnosis And Increased Financial Burden To Hamper The Market Growth

Cancer has a significant financial impact on patients and their families. Today, the estimated 16.1 million cancer patients face annual out-of-pocket medical expenses that are 61% higher than those who do not have cancer. Cancer patients had higher out-of-pocket costs than non-cancer patients, with high-deductible health plans having the greatest out-of-pocket costs. According to a report by the National Coalition of Cancer Survivorship 47% of cancer patients reported financial burden in cancer care.

Buy Now

Cancer Testing Screening Industry Outlook

Product Launch, Collaboration, and Acquisitions key strategies adopted by players in the Cancer Testing Screening Market. In 2020, the Cancer Testing Screening Market share is consolidated by the top ten players present in the market. In the Cancer Testing Screening Market, the top 10 companies are-

DiaSorin S.p.A

Immunodiagnostic Systems Holdings Ltd

Epigenomics AG

Quest Diagnostics Inc.

F. Hoffmann-La Roche Ltd

VolitionRX Limited

Abbott Laboratories

QIAGEN GmbH

Siemens Healthineers AG

Becton, Dickinson, and Company

Recent Developments

In January 2022, Siemens Healthineers, through its subsidiary Varian entered into a ten-year strategic partnership with Oulu University Hospital in Finland, to build a comprehensive digital, diagnostic and therapeutic ecosystem that addresses the entire cancer treatment pathway. Siemens will supply a technology and services package to Oulu University Hospital that includes cancer imaging and radiation therapy equipment, software solutions for enhanced workflow and decision support, and related support services.

In February 2022, Becton, Dickinson, and Company acquired Cytognos, a company specializing in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection, and immune monitoring research for blood diseases. The acquisition enables BD to enhance chronic illness management by increasing its offering of blood cancer diagnostics, immunological assessment tests, and informatics.

In October 2021, Roche entered into a collaboration with PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology. Under the agreement, the companies are to jointly develop an embedded image analysis workflow for pathologists, which can benefit cancer patients through more precise diagnosis. 

[debanish]

Road Trip: 6,000 Km, 7 States, 2 Plates Of Kolhapuri Chicken, And 1 Orange

A short highway drive led to this blog post. Three of us drove down from Delhi to Goa via Udaipur and Mumbai. After getting sunburn for three days in Goa, we drove onwards to a town near Mangaluru to see the beaches.

No one gives a samosa these days, so this post will omit annoyances like scenery, sunset, wanderlust, the mountains-are-calling, and I-love-travel nonsense.

My mother is used to hearing unpleasant, unexpected things from people about me. When word reached her that I have decided to drive down south thousands of kilometres with some people from Delhi, with the possibility that I may drive back home alone for a few thousand kilometres more, she tried to change my mind.

"No, no, no," she said on the phone at night, far away from Imphal. "It's very dangerous. What if you get hurt in an accident, or worse?"

"Accidents happen all the time," I said. "But we will be fine," I told her, not entirely sure about that. Who can predict the future? After a while she agreed she would be cool about it.

Mothers are like that. But they will let you go eventually. They know that you, too, have been collecting years.

We set out for Udaipur from Delhi at 6 am. A lab in Jaipur, a city that falls on our route, agreed to take samples for COVID-19 test. Any cop at state borders could ask for an RT-PCR report even if you are fully vaccinated. Whatever the cop says is final when you are travelling by road, so we decided to be well-prepared. The only chai-paani I like is the one I have myself.

We reached Udaipur at 9 pm. For dinner, we ordered Rajasthani laal maans. This drive across seven states - Delhi, Haryana, Rajasthan, Gujarat, Maharashtra, Goa, and Karnataka - opened up infinite possibilities of tasting the best food in each state.

We entered the Gujarat border at 10 am. A police officer stopped us to check documents and asked, "Carrying any daaru?" We said no, of course, and he let us through.

Next came the Godhra bypass, a state highway with a smooth surface and proper markings that made driving quite fun. The state highways in Gujarat are better than some national highways.

Baroda, Surat and hunger followed soon. We drove past dhaba after dhaba with "only veg" and "pure veg" signboards, until we found one with a poster that showed an omelette. This, we blamed the Bengali in the car.

Over 13 hours of driving put us right on the doorstep of Navi Mumbai. Pushing and fighting your way inside a coach in Delhi's busy Rajiv Chowk metro station is way easier than entering Mumbai during evening rush hour traffic.

There are two main routes from Mumbai to Goa. The first is a twisty old highway that passes through ghat roads, and the second is a straight run on the plains via Pune and Kolhapur. Many prefer the second route because why not? The old highway is full of potholes, back pain and feelings about taking a U-turn for home ASAP.

We stopped at Kolhapur bypass for Kolhapuri chicken. See for yourself in the photo below.

The road from Nipani in Karnataka all the way to the Goa border is narrow. But it was on this stretch that we liked stopping for tea and filter coffee.

We reached Goa at night on Day 3 after we drove out from Delhi.

Some days later we prepped for the ride to our next destination - Surathkal, a clean, green, and quiet beach town 20 km from Mangaluru in Karnataka.

Fish thaali in Karwar, on the Karnataka-Goa border, and filter coffee in Udupi really charged up the drive to Surathkal, where we reached in no time and stayed at a friend's house, just a 10-minute walk from a white, sandy beach.

We chilled at Surathkal for two days, visited Mangaluru and enjoyed ghee roast chicken and gadbad ice-cream.

When the time to return home came, a small but not an entirely unexpected problem presented itself like magic. See, I drove down with two friends all the way from Delhi, but they flew back to attend a wedding. A stern message came from home that either I find someone to ride shotgun on the return leg, or I give the car to Agarwal Packers and Movers and fly back. I cannot drive back alone, the serious people at home said.

The only person who came to mind was an old friend from school, who in Class 12 taught me how to drive a motorcycle wrong and wreck it. By now we go back a quarter of a century. I dialled him and presented the plan - he would fly down to Goa, stay for a day, and drive back with me to Delhi with a night's stop each in Mumbai and Udaipur. "You can eat anything you like, stop anywhere you like," I told him. It did the trick. He took a flight to Goa within 24 hours with only a small backpack.

The return leg did not play out any different than how we had come. We traced back the same routes. The Godhra bypass had excellent reflective markings that made driving at night safe. The Rajasthan-Gujarat border near Udaipur had similar safety features. These two stretches helped a lot in improving night driving skills.

That's all people. And about that orange, I forgot where I had kept it for the entire trip. When I finally reached home, it tumbled out from the magazine holder of the front seat.

Fin.

The fine print:

Vehicle: Maruti Suzuki Ignis 1.2 petrol manual, stock tyres upsized by 20 mm to 195/60/R15, Continental UC6

Total toll cost: Rs 5,210 (as per FASTag statement)

Total fuel cost: Rs 28,000 (approximate)

Best roads: Udaipur to Gujarat border, Udaipur-Jaipur highway, Godhra bypass, Mumbai-Pune expressway, Udupi to Surathkal highway

Worst roads: 30 km from Amboli ghat to north Goa border, exit from Navi Mumbai to Thane, Gurgaon-Jaipur highway (road surface is relatively smooth, but it's really bad for night driving due to absence of lane markings on the road; you can get blinded with oncoming headlights and not find directional help since the white lines on the road are missing)

Recommended dhabas and restaurants: Shree Mahalaxmi Seafood Restaurant, Kolhapur bypass; Shetty Lunch Home, Mangaluru; Cafe de Voyage, Margao; Laxmi Family Restaurant and Bar, Morjim.

Thanks to Ira, Jayashree, Munmun, Stella, Rajib, Smitha and Jayant for the company during the road trip and taking these photos.

[screenshots123]

📆 28 Nov 2023 📰 Covid check: Do it right 🗞 Bangalore Mirror

As many doctors were referring to CT scans to determine covid positivity instead of RT PCR test, the government has ordered that CT scans shouldn't be done on covid suspects before subjecting them to RT PCR, and only if the patient tests positive can a CT scan be referred.

Health Minister Dinesh Gundu Rao said, "The covid sub-committee has taken this decision to stop fleecing patients as many doctors were asking for CT scans for every such case."

Reacting to this, city doctors said that the Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) was often considered the 'gold standard' test for the detection of covid cases. However, during the first and second waves, there were a lot of false negatives with RT-PCR, and hence experts were depending on the CT thorax scan as it gave them a clear picture of the viral infection.

A city-based doctor said, "Whenever people visit me with fever, I recommend that they take a RT- PCR test. However, many are refusing to take the test due to the stigma attached to it.

Hence, I am asking them immediately to go for a scan, which can give the correct picture. There are ample examples where the patient might have been tested negative..."

Another medical expert said that in the case of a rapid antigen test (RAT), people who are having fever, cough, or any other covid-19 symptoms will test positive in the RAT only after a period of five days to one week. The sensitivity of this test ranges from 50% to 60%. There are possibilities of missing positive cases, which are also known as 'false negative' results. Therefore, if someone has gone for a test earlier, they may test negative.

The second test that is currently available and is considered the 'Gold Standard' for covid-19 testing is RT-PCR, which has a sensitivity of 60% to 70%. This test depends on the prevalence of covid infection in a person.

If the prevalence is high, then the person will definitely test positive for covid, and chances are that their RT-PCR will show a sensitivity of 80%.

However, there are chances that the remaining 20% of patients may walk out freely with a "negative" report in hand, as the prevalence of their virus may not be much in their bodies.

Hence, the CT thorax scan was recommended, which can provide a test report with a diagnostic value of more than 90%-95% accuracy. Even though it does not provide a 100% positive report, it can help clinicians understand the pattern of the diseases based on the scan report. It is true that symptomatic patients may show a negative RT-PCR result due to irregular and intermittent shedding of viruses or low or nil viral loads in the nasal swab area.

[straitsresearchreports]

Influenza Diagnostics Market Insights: A Forecast Analysis for 2031 and Beyond

Influenza Diagnostics Market Overview

Straits Research, a leading market research and intelligence company in India, has published the latest report on the “Influenza Diagnostics Market” where you will find all the in-depth information regarding the industry.

The global influenza diagnostics market size was valued at USD 645.31 million in 2019 and is expected to grow at 7.7% CAGR during the forecast study period.

The Global Influenza Diagnostics Market report published by Straits Research analyses the growth potential of the said industry across various industrial segments. It brings forth a detailed study of the influencing factors of the market that includes the growth drivers, restraints, opportunities, challenges and the recent developments of the major key players in the said industry along with an estimated CAGR for the global Influenza Diagnostics market.

Competitive Analysis – 

The “Influenza Diagnostics Market” report published offers a detailed in-depth analysis of the competitors operating in the industry with every inch of detail like history, financial and organizational growth, recent updates till the date the report is being published, etc. along with the forecasts of respective competitors.

Get a Free Sample Report of the Global Influenza Diagnostics Market @ https://straitsresearch.com/report/influenza-diagnostics-market/request-sample

F. Hoffmann-La Roche AG

Quidel Corporation

Thermo Fisher Scientific

Abbott Laboratories

Hologic, Becton

Dickinson and Company

DiaSorin S.p.A

Luminex Corporation

Meridian Bioscience

GenMark Diagnostics

SA Scientific

Sekisui Diagnostics

bioMérieux SA

Danaher Corporation

Siemens Healthineers

Altona Diagnostics

CorisBioConcept

Are you concerned about the genuineness of the report? No need to worry! Get a FREE sample of our market reports and develop trust within our reports.

Research Methodology:

The global Influenza Diagnostics market report is prepared with an in-depth research process by following stringent guidelines and methodologies to offer you an accurate forecast for revenue generation and growth rate.

The overall market study is done through the data mining process by analyzing the revenues of the key vendors through sources like websites, annual reports, press releases, white papers, and government publishing sources.

Market Segmentation:

By Test Type

Traditional Diagnostic Test

RIDT

Cell Culture

DFA

Serological Assays

Molecular Diagnostic Test

RT-PCR

INNAT

TMA

LAMP

NASBA

Other INNAT

Other Molecular Tests

By Influenza Type

Influenza A

Influenza B

By End-User

Hospital

Point-of-Care Testing

Diagnostic Centers

Others

The Global Influenza Diagnostics Market Report forecasts the revenue growth with respect to significant geographies like -

North America (U.S., Canada)

Europe (U.K., Germany, France, Italy)

Asia-Pacific (China, India, Japan, Singapore, Malaysia)

Middle-East & Africa

Latin America (Brazil, Mexico)

For example, in the Influenza Diagnostics Market, the North American region has its dominance over the global market, which is explained in detail with the requisite figures in this report. Thus the report offers an in-depth analysis of the latest industry trends and developments in each of the segments and sub-segments for the forecasted period of 2023-2031. The report also studies various sub-segments and classifications of the Global Influenza Diagnostics Market.

Buy Now: https://straitsresearch.com/buy-now/influenza-diagnostics-market

Key Findings of the Report:

The Global Influenza Diagnostics market report studies the market thoroughly and provides an approximate forecast for 2023-2031.

The said report includes an in-depth analysis of the latest developments in the Global Influenza Diagnostics market.

The report provides an easy-to-understand market definition and a list of leading players with their strategies to determine the market's competitive outlook.

The report also studies the drivers, restraints, opportunities, and challenges for the global Influenza Diagnostics market.

The Influenza Diagnostics market report provides historical data and forecasts revenue of the market segments and sub-segments for the main geographies including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The market for Influenza Diagnostics is partially consolidated and competitive, with the presence of leading players that contribute to the overall growth of the Influenza Diagnostics market.

Other features of the report:

The report analyzes key strategies focusing on the corporate structure, R&D methods, localization strategies, production capabilities, sales, and performance in various companies. 

It provides valuable insights into the product portfolio, including product planning, development, and positioning in the global market.

The said report thoroughly studies the role of key players in the global Influenza Diagnostics market, along with their business developments and collaborations.

Latest Related Reports

https://www.wowonder.xyz/read-blog/38187

https://educatorpages.com/site/businessoutlook/pages/intracranial-pressure-monitoring-devices-market-challenges-to-2031

With all this detailed information specified related to the Global Influenza Diagnostics market, you might be interested to know more about the said market segment, for which you need to get the detailed research report of the Global Influenza Diagnostics Market published by Straits Research.

For that, you just need to click on the link below, do the transaction and get the report delivered to your mail-id. 

It's as Simple as That!

Click here to buy the Global Influenza Diagnostics Market Report by Straits Research.

[typoeastnews]

India Issues Urgent Advisory Amidst Surging Covid Cases

In response to the alarming spike in Covid-19 cases across India, the Centre issued a crucial advisory on Monday, urging all states to step up their efforts in combating the pandemic. According to data from the Union Health Ministry, India reported 260 new coronavirus infections in the last 24 hours.

In a letter addressed to the Health Secretaries of all states and Union Territories, the government emphasized the need for constant vigilance and prompt action to curb the spread of the virus. States were directed to closely monitor and report district-wise Severe Acute Respiratory Illness (SARI) and Influenza-like Illness (ILI) cases on a regular basis.

The advisory highlighted several key measures that states should implement immediately:

Public Health Measures: States were advised to implement necessary public health measures and arrangements to minimize the risk of Covid-19 transmission.

Compliance with Operational Guidelines: States were urged to ensure effective compliance with detailed operational guidelines for the revised surveillance strategy, as provided by the Union Ministry of Health and Family Welfare.

Testing and Reporting: The Centre stressed the importance of adequate testing, including a higher number of RT-PCR tests. States were instructed to report and monitor district-wise ILI and SARI cases regularly, using the Integrated Health Information Platform (IHIP) portal.

Genome Sequencing: States were advised to send positive samples for genome sequencing to INSACOG laboratories to enable timely detection of new variants, considering the recent detection of the JN.1 variant in Kerala.

Community Awareness: States were encouraged to actively promote community awareness and seek continued public support in managing Covid-19, emphasizing adherence to respiratory hygiene.

The advisory comes in the wake of India detecting its first case of the JN.1 variant in Kerala. The 79-year-old patient with mild Influenza-like symptoms has fully recovered. Kerala Health Minister Veena George reassured the public, stating that the JN.1 variant had been detected months ago in Indian passengers screened at Singapore Airport. While causing a surge in infections worldwide, health authorities remain vigilant, especially given its spread to over 20 countries since its identification in Luxembourg.

The government's advisory underscores the critical need for proactive measures and collaboration between public and private health facilities to effectively manage the evolving situation.